Abstract
Nicotinic receptors generally are presumed to consist of two α and three non-α subunits. We varied the relative levels of expression of the neuronal nicotinic α4 and β2 receptor subunits inXenopus laevis oocytes by nuclear injection of cDNAs coding for these subunits in α:β ratios of 9:1, 1:1, and 1:9. The sensitivities of the receptors to acetylcholine andd-tubocurarine were investigated in voltage-clamp experiments. For receptors expressed at the 9:1 and 1:1 α:β ratios, the EC50 value of acetylcholine is ∼60 μm. For the majority of the receptors expressed at the 1:9 α:β ratio, the sensitivity to acetylcholine is enhanced 30-fold. No evidence for more than one type of acetylcholine binding site in a single receptor is obtained. The sensitivity to d-tubocurarine decreases with decreasing α:β ratio. IC50 values ofd-tubocurarine are 0.2, 0.5, and 2 μm for the 9:1, 1:1, and 1:9 α:β ratios, respectively. At the 1:9 α:β ratio, additional receptors with an IC50 value of 163 μm d-tubocurarine are expressed. At least two components with distinct sensitivities tod-tubocurarine are required to account for the shift in IC50. The combined agonist and antagonist effects reveal four distinct subtypes of α4β2 nicotinic receptors. The results imply that the subunit stoichiometry of heteromeric α4β2 acetylcholine receptors is not restricted to 2α:3β.
Neuronal nAChRs are ligand-gated ion channels present throughout the central and peripheral nervous systems. Multiple neuronal nAChR subunits (α2–9 and β2–4) have been identified. These subunits combine in various compositions to form pentameric receptors with different functional and pharmacological characteristics (reviewed in McGehee and Role, 1995).
The α4 and β2 nAChR subunits are expressed abundantly in brain (Wada et al., 1989), and the most common nAChR in the brain is composed of these two subunits (Whiting et al., 1990;Flores et al., 1992). The subunit stoichiometry of α4β2 nAChRs expressed in Xenopus laevis oocytes has been deduced to be α4:β2 = 2:3 (Anand et al., 1991; Cooperet al., 1991), and the subunits are assumed to be arranged around the central ion channel pore in the order βαβαβ (Anandet al., 1991). Patch-clamp recording from oocytes expressing pairs of α and β nAChR subunits revealed ACh-gated single channels with distinct conductances (Papke et al., 1989; Papke and Heinemann, 1991; Charnet et al., 1992; Kuryatov et al., 1997). The frequency of occurrence of the different single-channel conductance states depends on the α:β ratio of the mRNA mixture injected into the oocyte, indicating that receptors with different subunit stoichiometry are expressed (Papke et al., 1989).
The agonist binding sites of heteropentameric neuronal nAChRs generally are supposed to be located at the two αβ subunit interfaces (reviewed in Bertrand and Changeux, 1995). Functional nAChRs with distinct subunit stoichiometries might differ with respect to the number and properties of agonist binding sites. We investigated the functional properties of the agonist binding sites in X.laevis oocytes expressing different levels of α4 and β2 nAChR subunits. The results on concentration-dependent effects of the agonist ACh and of d-TC, a competitive antagonist of α4β2 nAChRs (Bertrand et al., 1990), demonstrate four distinct subtypes of α4β2 nAChRs.
Experimental Procedures
Materials.
X. laevis were bred and kept in the Hubrecht Laboratory (Utrecht, The Netherlands) or were bought from Nasco (Fort Atkinson, WI) and kept in our own laboratory. Neomycin was obtained from Sigma Chemical (St. Louis, MO). d-TC was from Fluka (Buchs, Switzerland). All other materials used came from sources identical to those described previously (Zwart and Vijverberg, 1997).
Receptor expression.
Oocytes were prepared, injected, and incubated in Barth’s solution containing 5 mg/liter of neomycin at 19° for 3–7 days as described previously (Zwart et al., 1995; Zwart and Vijverberg, 1997). Plasmids coding for α4 and β2 subunits of neuronal nAChRs were dissolved in distilled water at the approximately equal concentrations of 152 ± 15 and 136 ± 12 μg/ml (mean ± standard deviation of triplicate spectrophotometric determinations), respectively. Unless noted otherwise, mixtures of these solutions at 1:9, 1:1, and 9:1 ratios were coinjected at 18.4 nl/oocyte.
Electrophysiology and data analysis.
Oocytes were placed in a silicon rubber tube (diameter, 3 mm), penetrated by two microelectrodes, and voltage clamped at −80 mV. ACh and d-TC, dissolved in external solution, were applied by perfusion of the tube at a rate of ∼20 ml/min. The external saline contained 115 mm NaCl, 2.5 mm KCl, 1 mmCaCl2, and 10 mm HEPES, pH 7.2, with NaOH. Voltage-clamp equipment, experimental protocols, and data acquisition were exactly as described previously (Zwart and Vijverberg, 1997). All amplitudes of ACh-induced ion currents were normalized to the amplitude of alternately evoked control responses to a near-maximum effective concentration of ACh to adjust for small variations in response amplitude over time. Data are expressed as mean ± standard deviation of number of oocytes. ANOVA was performed using Microsoft Excel. Results were compared using a two-tailed Student’st test. Concentration-effect curves were fitted, using Jandel SigmaPlot software, to data obtained in separate experiments, and mean ± standard deviation values of estimated parameters were calculated for three oocytes. Curves drawn in the figures were generated using the mean values of the estimated parameters. Agonist data were fitted according to the equationsi/i max =E max/[1 + (EC50/[ACh])nH] and i/i max =E maxa/(1 + EC50a/[ACh]) +E maxb/(1 + EC50b/[ACh]) for one- and two-component activation curves, respectively. Antagonist data were fitted according to the equations: i/i max = 1/[1 + ([dTC]/IC50)nH] and i/i max =E m/[1 + ([dTC]/IC50a)nHa) + (1 − E m)/[1 + ([dTC]/IC50b)nHb] for one- and two-component inhibition curves, respectively. In these equations, [ACh] and [dTC] are the concentrations of ACh and d-TC, respectively; nH is the Hill coefficient; and i/i max is the normalized current amplitude. Goodness-of-fit was judged by analysis of the residuals (run test).
Results
Effects of α4:β2 ratio on ion current amplitude.
Superfusion of voltage-clamped oocytes, expressing α4β2 nAChRs after the injection of α4 and β2 subunit cDNAs in the α:β ratios 1:9, 1:1, and 9:1, with 300 μm ACh results in ligand-gated ion currents. The effect of subunit ratio on response amplitude was investigated in the same batch of oocytes because expression levels vary between batches. The amplitude of the inward current induced by the near-maximal effective concentration of 300 μm ACh at the holding potential of −80 mV depends on the α4:β2 subunit cDNA ratio injected into the oocytes (Fig.1). The largest inward currents are observed in oocytes injected with α4 and β2 subunit cDNAs in the 1:1 ratio. At both the 1:9 and 9:1 α:β ratios, amplitudes of inward currents evoked by 300 μm ACh are reduced significantly (t test; p < 0.001). Some oocytes (9 of 54) that did not respond to ACh at all, most likely because the cDNA was not properly injected into the nucleus, were excluded from the analysis. The results show that, after injection of the α4 and β2 subunit cDNAs in extreme ratios, while maintaining the total cDNA injected approximately constant, inward current amplitudes are reduced. This indicates that after injection of cDNAs in the α:β ratios of 1:9 and 9:1, response amplitude is limited by the availability of α and β subunits, respectively. After injection of the same total amounts of either cDNA encoding the α4 subunit only or cDNA encoding the β2 subunit only, oocytes did not respond to 300 μmACh (results not shown). This demonstrates that α4 and β2 subunits do not form functional homopentameric nAChRs. The absence of ACh-induced inward current also shows that α4 and β2 do not form functional heteromeric nAChRs with native nAChR subunits that possibly are present in X. laevis oocytes (Buller and White, 1990).
Effects of α4:β2 ratio on the agonist concentration-effect curve.
Agonist concentration-effect curves were obtained from oocytes expressing α4β2 nAChRs after the injection of subunit cDNAs in the α:β ratios of 1:9, 1:1, and 9:1. Examples of ACh-induced ion currents are shown in Fig. 2A for the different subunit cDNA ratios tested.
From Fig. 2A, it is apparent that inward currents evoked by high concentrations of ACh show an acceleration of inward current decay. In addition, a “tail” inward current is observed on removal of the agonist. These effects are commonly attributed to the onset and reversal of ion channel block by high concentrations of ACh (Colquhoun and Ogden, 1988; Oortgiesen and Vijverberg, 1989). For the different α:β ratios, inward current decay in the absence of overt ion channel block (i.e., for responses evoked by superfusion with 300 μm ACh) was quantified by dividing the inward current at the end of ACh application (t = 10 sec) by the peak inward current. The inward current decayed to 61 ± 16% (5 oocytes) of the peak value for the 1:1 α:β ratio, to 51 ± 11% (7 oocytes) for the 9:1 α:β ratio, and to 82 ± 4% (14 oocytes) for the 1:9 α:β ratio. The degree of inward current decay at the 1:9 ratio differs significantly from that at the 1:1 and 9:1 α:β ratios (t test; p < 0.05).
For each of the α:β subunit cDNA ratios investigated, the amplitudes of peak inward current evoked by superfusion of 0.1 μm to 10 mm ACh were normalized to those of 1 mm ACh-induced inward currents in three oocytes. Two-way ANOVA of the results obtained with ACh at concentrations of ≤1 mm showed that the data for the 1:1 and 9:1 α:β ratios cannot be distinguished statistically (F1,28 = 0.1441, p = 0.71) and that both sets of data differ statistically from the data obtained for the 1:9 ratio (p < 0.001). Concentration-effect curves of ACh were fitted for each α:β ratio. The data of the 1:1 and 9:1 α:β ratios are closely approximated by one-component sigmoidal curves (Fig. 2B). In all cases, data measured at the higher ACh concentrations, which induce ion channel block, were excluded from the curve-fitting procedure. For the 1:9 α:β ratio, the concentration-effect curve shows a striking shift toward lower agonist concentrations, and the slope of the data is markedly reduced. Together with the inflection point in the data observed between 10 and 100 μm ACh (Fig. 2B), this suggests the presence of two components with distinct sensitivities to the agonist. A one-component concentration-effect curve did not fit the data adequately as indicated by analysis of the residuals (run test; p < 0.05). The data obtained for concentrations of <1 mm ACh could be fitted by a two-component concentration-effect curve only with fixed values of the slope factors. EC50 values of 1.74 and 144 μm ACh and E maxvalues of 85% and 43%, respectively, were obtained when the slope factors were set to 1. Due to the small number of data available for curve fitting at high agonist concentrations, reliable estimates for the less-sensitive component cannot be obtained. A one-component concentration-effect curve fitted to the data obtained with ACh at concentrations of ≤30 μm yielded EC50, nH , andE max values of 1.84 μm ACh, 1.05, and 89.3%, respectively (Table1). The two concentration-effect curves both seem to fit the more-sensitive component accurately (Fig. 2B). The large E max value of the more-sensitive component of the concentration-effect curve indicates that the majority of nAChRs expressed at the 1:9 α:β cDNA ratio are highly sensitive to ACh. Oocytes injected with cDNAs encoding α3 and β2, or α4 and β4, in a 1:9 α:β ratio did not show enhanced sensitivity to ACh compared with oocytes injected with these subunit cDNAs in a 1:1 α:β ratio (not shown).
From the ANOVA of the data and from the EC50values estimated from the concentration-effect curves (Table 1), it is concluded that depending on the ratio of α4 and β2 subunit cDNAs injected, two distinct types of functional nAChRs are expressed in oocytes with ∼30-fold difference in sensitivity to ACh.
Effects of α4:β2 ratio on the antagonist concentration-effect curve.
Concentration-effect curves for the competitive nAChR antagonist d-TC also were obtained from oocytes expressing α4β2 nAChRs after the injection of subunit cDNAs in the α:β ratios of 1:9, 1:1, and 9:1. Examples of ion currents evoked by superfusion of 300 μm ACh in the absence and the presence of various concentrations of d-TC are shown in Fig.3A for the different subunit cDNA ratios tested. d-TC was superfused ≥4 min before an ACh-induced current was recorded in the presence of d-TC. For three oocytes of each α:β subunit cDNA ratio tested, peak inward current amplitudes were normalized to those of control inward currents evoked by 300 μm ACh in the same oocyte. The normalized data are plotted against d-TC concentration in Fig. 3A. ANOVA of the inhibitory effects of d-TC showed that the data for the different subunit cDNA ratios all are statistically different at the p < 0.001 level. For the 9:1 and 1:1 α:β subunit cDNA ratios, data could be fitted by a one-component concentration-effect curve. However, for the 1:9 ratio, the concentration dependence of inhibition by d-TC seemed to be biphasic, and fit was significantly improved by fitting a sum of two concentration-effect curves to the data (Fig. 3A). Estimated values of the parameters of the fitted concentration-effect curves are presented in Table 2. The inhibitory effects of d-TC on α4β2 nAChRs at the 1:1 α:β ratio also were investigated at a holding potential of −40 mV (result not shown). The IC50 value for d-TC of 0.91 ± 0.48 μm (three oocytes) at −40 mV could not be distinguished from that obtained at the holding potential of −80 mV. Thus, it seems that voltage-dependent ion channel block, observed previously for muscle-type nAChRs at high concentrations of d-TC (Colquhoun et al., 1979), does not strongly contribute to the inhibitory effects of d-TC observed at concentrations of ≤10 μm.
Additional experiments were performed to investigate the relation between the two components of inhibition by d-TC (Fig. 3A) and the two components of ACh sensitivity (Fig. 2B) for the 1:9 α:β ratio. Inward currents were evoked by superfusion with 10 μm ACh to selectively activate the more sensitive nAChRs. The data on the inhibition of 10 μm ACh-induced inward current by d-TC are well fitted by a one-component concentration-effect curve (Fig. 3B) with an IC50 value (see Table 2) that cannot be distinguished from that of the more-sensitive component of inhibition of 300 μm ACh-evoked responses (t test;p = 0.11). Comparison of the inhibition curves of d-TC obtained with 10 and 300 μm ACh (Fig. 3B) shows that at the 1:9 α:β ratio, two subtypes of nAChRs are expressed: one subtype more sensitive to ACh and one less sensitive to d-TC than the receptors expressed at the other α:β ratios, and a second subtype with low sensitivity to ACh and very low sensitivity to d-TC. The IC50 of d-TC shifts toward higher concentrations with decreasing α:β ratio (ANOVA; p values < 0.001), and the IC50 values of d-TC obtained at the different α:β ratios differ statistically (t test;p values < 0.01; Table 2).
To investigate the mechanism of inhibition of the component of nAChR-mediated ion current with a very low sensitivity to d-TC observed at the 1:9 α:β ratio, oocytes were continuously superfused with 30 μm d-TC to eliminate the more-sensitive component (see Fig. 3A). Inward currents evoked by superfusion with 100 μm ACh in the presence of 30 μm d-TC, which represent the less-sensitive component, and after preexposure to 330 μm d-TC for 4 min were recorded to establish low affinity inhibition. Inward currents evoked at a holding potential of −60 mV were reduced by 81.7 ± 1.6% (three oocytes) by increasing the concentration of d-TC from 30 to 330 μm (Fig.4A). In the same oocytes, low affinity inhibition at a holding potential of −100 mV (Fig. 4B) amounted to 86.9 ± 2.4%. The small difference is statistically significant (t test; p < 0.05), indicating some voltage dependence of the inhibitory effect. Inward currents evoked by coapplication of 100 μm ACh and 330 μm d-TC show a reduction in the peak amplitude and a rapid further onset of inhibition by d-TC during the response (Fig. 4C). At the steady level of inhibition, which was achieved within a few seconds, the amount of reduction of the inward current is the same as that obtained with preexposure to d-TC. The apparent absence of kinetic effects after preexposure to d-TC (Fig. 4, A and B) and the absence of a pronounced tail current on removal of the high concentration of d-TC (Fig. 4C) indicate that ion channel opening is not required for the inhibitory effect. Together with the weak voltage dependence of inhibition, these results indicate that even at high concentrations, d-TC does not cause significant ion channel block.
Effects of nAChR expression level on agonist and antagonist sensitivities.
Because it cannot be excluded that nAChR expression level by itself affects agonist and antagonist sensitivity, experiments were performed on oocytes injected with diluted 1:1 α:β cDNA solution at constant injection volume. In oocytes injected with a 10-fold diluted cDNA solution, superfusion with 1 mm ACh did not evoke detectable (>5 nA) inward currents (10 oocytes). This indicates that nAChR expression is greatly reduced, consistent with previous results on the expression level of chick α4β2 nAChRs in oocytes (Bertrand et al., 1991). After the injection with a 4-fold diluted cDNA solution, ACh-induced ion currents were evoked, which were smaller than those obtained before but had a similar shape (Fig. 5A). The inward current decay at the end of ACh application amounted to 48 ± 15% (five oocytes) of the peak current. This cannot be distinguished from the degree of decay at the higher expression level (t test;p = 0.24) but differs from the degree of inward current decay obtained for the 1:9 α:β ratio (p < 0.01). Agonist and antagonist sensitivities were determined from six oocytes with a maximal peak inward current amplitude of 398 ± 82 nA (i.e., in the same range as with the 1:9 and 9:1 α:β ratios). The results obtained with ACh at concentrations of ≤1 mmfrom oocytes with high and low level nAChR expression at the 1:1 α:β ratio are not identical (two-way ANOVA; F1,28 = 7.556, p = 0.01). Although the fitted concentration-effect curve of ACh (Fig. 5A, Table1) shows a small shift toward higher concentrations, the EC50 and nH values cannot be distinguished from those obtained for the higher expression level (t test; p > 0.08). The concentration-effect curve of d-TC at the low expression level (Fig.5B, Table 2) cannot be distinguished statistically from that obtained with the high expression level at the 1:1 α:β ratio (two-way ANOVA; F1,20 = 2.290, p = 0.15). However, this curve differs from the inhibition curves obtained for the 9:1 and 1:9 α:β ratios (two-way ANOVA; p < 0.001). Further statistical analysis showed that the expression level does not influence the IC50 value of d-TC (t-test; p = 0.33) and that regardless of expression level, distinct IC50 values are obtained for the different subunit ratios (t test;p values < 0.01). From the combined results, it is concluded that reducing the nAChR expression level causes only a small decrease in ACh sensitivity, which is opposite the 30-fold increase in sensitivity observed at the 1:9 α:β ratio.
Discussion
Differences in agonist and antagonist sensitivities of receptors expressed in oocytes after injection of cDNAs coding for the α4 and β2 subunits at 1:9, 1:1, and 9:1 ratios demonstrate heterogeneity of α4β2 nAChRs. The results show that combinations of α4 and β2 subunits form four pharmacologically distinct subtypes of heteromeric nAChRs. Two subtypes of nAChRs, which are distinguished for the 1:1 and 9:1 α:β ratios, have similar low sensitivities to ACh (EC50 ≈ 60 μm) but distinct sensitivities to d-TC (IC50 = 0.20 and 0.53 μm, respectively). Two additional, distinct subtypes of nAChRs are formed at the 1:9 α:β ratio: one subtype with markedly enhanced sensitivity to ACh (EC50 = 1.8 μm) and decreased sensitivity to d-TC (IC50 = 2.04 μm), and a second subtype with low sensitivity to ACh and very low sensitivity to d-TC (IC50 = 163 μm). Heterogeneity of neuronal nAChRs has been suggested before from the observation that the occurrence of distinct single-channel conductances in oocytes expressing neuronal-type nAChRs depends on α:β ratio (Papkeet al., 1989).
The effects of varying α:β ratio on the properties of nAChRs were investigated in oocytes injected with approximately equal total amounts of cDNA (2.5–2.8 ng/oocyte). The reduced response amplitudes at the 1:9 and 9:1 ratios indicate that the availability of α and β subunits limits functional receptor expression at these cDNA ratios (Fig. 1). A comparison of the properties of nAChRs expressed at a reduced level for the 1:1 α:β ratio (Fig. 5) with those of nAChRs expressed at the 1:9 and 9:1 ratios (Figs. 2, 3) demonstrates that the 30-fold difference in sensitivity to ACh, the shift in sensitivity to d-TC, and the differences in the degree of inward current decay are due to changes in subunit ratio and not to differences in expression level.
The properties of ligand-gated ion channels depend on subunit composition. Combining α4 and β2 subunits into a pentameric nAChR protein theoretically can yield eight distinct subtypes of the α4β2 nAChR. The two homopentameric α4 and β2 nAChRs are not expressed or are not functional. Six heteropentameric subunit assemblies remain: four α:β subunit stoichiometries (1:4, 2:3, 3:2, and 4:1) and two alternative subunit arrangements for the 2:3 and the 3:2 stoichiometries (Fig. 6). Of these six, at least four have been demonstrated to form pharmacologically distinct, functional nAChRs. This implies that functional α4β2 nAChRs are formed with other than the 2:3 α:β subunit stoichiometry.
Functional heteropentameric neuronal nAChRs presumably contain two binding sites for ACh located at the αβ interfaces (Luetje and Patrick, 1991; Bertrand and Changeux, 1995). However, only two of all possible subunit assemblies contain two αβ interfaces (Fig. 6). The conclusion that four distinct types of α4β2 nAChRs are formed implies that agonist binding at one or more of the βα, ββ, or αα subunit interfaces may be involved in ion channel activation or that binding of a single agonist molecule is sufficient to activate α4β2 nAChRs. The latter would be consistent with the results because the slopes of the concentration-effect curves of ACh all are close to 1 (Table 1). Shallow slopes of the concentration-effect curve of ACh on α4β2 nAChRs generally are reported: in oocyte studies, 0.81 for rat α4β2 (Stafford et al., 1994), 1.5 for chick α4β2 (Bertrand et al., 1990), and 1.02 for human α4β2 (Chavez-Noriega et al., 1997), and in human embryonic kidney 293 cells, 1.2 for human α4β2 (Buisson and Bertrand, 1998). In α7 nAChRs, αα interfaces contribute to ligand binding. This homopentameric nAChR seems to contain five binding sites for the competitive antagonist methyllycaconitine (Palma et al., 1996). The α7 subunit contains the principal component (loops A–C) as well as the highly conserved residue Trp54, which constitutes part of a complementary component of the proposed agonist binding site. These two components of the agonist binding site in α7 are thought to be equivalent to those contained by the muscle-type α1 and the γ and δ nAChR subunits, respectively. The α4 subunit contains the principal component of the agonist binding site as well as a tryptophan residue homologous to Trp54 in α7. The β2 subunit contains the complementary component of the agonist binding site as well as loops A and B of the principal component (Corringer et al., 1995). The homology among α4, β2, and α7 suggests that αα, βα, or ββ subunit interfaces also might form functional agonist or antagonist binding sites. The shift in agonist sensitivity seems to be specific for the α4β2 nAChRs because it is not observed when α3β2 and α4β4 nAChRs are expressed at 1:1 and 1:9 α:β cDNA ratios (Luetje and Patrick, 1991). This indicates that neither αα nor ββ subunit interfaces are directly involved in the change in sensitivity to ACh.
The results show that the inhibitory effects of d-TC on α4β2 nAChRs are not due to ion channel block. Low concentrations of d-TC have been shown to inhibit neuronal nAChRs by a competitive interaction before (Bertrand et al., 1990), but the exact nature of the inhibitory effect of the very high concentrations of d-TC on nAChRs at the 1:9 α:β ratio remains to be investigated. However, the four distinct IC50 values for d-TC do not necessarily imply that α4β2 nAChRs contain four distinct binding sites for d-TC. Apart from the component with very low sensitivity, the effects of d-TC consist of monophasic inhibition curves with shallow slopes, which gradually shift to higher concentrations with decreasing α:β ratio (Fig. 3; Table 2). This indicates that high and low affinity sites differentially contribute to the inhibitory effect of d-TC and cause shift of the IC50. Three two-component inhibition curves of d-TC were simultaneously fitted to the three sets of data obtained for the 9:1, 1:1, and 1:9 (10 μm ACh) α:β ratios. Hill coefficients were set to 1, and the IC50 values of d-TC and the relative proportions of the two effects of d-TC were estimated. This yielded IC50 values of 0.16 and 4.3 μmd-TC, regardless of α:β ratio. The estimated proportions of the more- and less-sensitive components changed with α:β ratio. The size of the more sensitive component decreased from 88% at the 9:1 α:β ratio to 62% and further to 26% at the 1:1 and 1:9 α:β ratios, respectively. The curves fitted according to the two-component inhibition model (Fig. 3) demonstrate that for α4β2 nAChRs, at least two sites with an estimated 27-fold difference in sensitivity to d-TC are required to account for the inhibitory effects observed. This is in the same order of magnitude as the 15- and 27-fold differences in sensitivity of α1β1γ and α1β1δ muscle-type nAChRs expressed in fibroblasts and human embryonic kidney 293 cells to d-TC and dimethyl-d-TC, respectively (Blount and Merlie, 1989; Sine, 1993). The shift in the inhibition curve of d-TC can be accounted for by assuming a minimum of two distinct sites for d-TC. The differential contribution of these sites to the inhibitory effect at different α:β ratios suggests that they are located on distinct subtypes of α4β2 nAChRs. The possibility that the high and low affinity components reflect effects of d-TC on a single population of receptors is highly unlikely. If the two sites would be present on the same nAChR, only the inhibition caused by the binding of d-TC to the high affinity site would have been detected. Some receptors seem to lack both sites because they are affected by d-TC at very high concentrations only.
The results with d-TC indicate that two subtypes of α4β2 nAChRs may be distinguished in oocytes injected with cDNAs at the 1:1 α:β ratio. In oocytes injected with cRNAs or cDNAs encoding chick α4 and β2 subunits at a 1:1 ratio, nAChRs seem to have a 2:3 α:β stoichiometry (Anand et al., 1991; Cooper et al., 1991). The current and the previous results are compatible when two subunit arrangements, which are possible for the 2:3 α:β stoichiometry (Fig. 6), are formed and have distinct sensitivities to d-TC. The diverging results on the number of conductance levels of single ion channels formed by α4β2 nAChRs at the 1:1 α:β ratio provide no conclusive evidence on α4β2 nAChR heterogeneity (Papkeet al., 1989; Cooper et al., 1991; Charnetet al., 1992; Kuryatov et al., 1997). Single-channel properties of α4β2 nAChRs at other than the 1:1 α:β ratio have not been reported. Whether the arrangement of subunits within a receptor affects single-channel properties remains unknown. The current results demonstrate that changing the relative abundance of subunits expressed by changing the cDNA ratio leads to alternative subunit assemblies with sensitivities to ACh and d-TC distinct from those obtained for nAChRs at the 1:1 α:β ratio.
The ratios of subunit cDNAs used in the current study for the expression of distinct subtypes of α4β2 nAChRs in oocytes are in the same order of magnitude as those found in brain. The ratio of α4:β2 mRNA levels in various regions of rat brain ranges between 1:1 and 1:15 (Liu et al., 1996). For α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors, it has been shown that the number of glutamic acid type 2 receptor subunits incorporated depends on the relative abundance of the glutamic acid type 2 receptor subunit expressed in oocytes as well as in rat hippocampal interneurons. The resulting differences in subunit stoichiometry of native and heterologously expressed α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors are associated with changes in channel function (Washburn et al., 1997). Although it was assumed previously that nAChRs have a fixed subunit stoichiometry, the current results show that α4β2 nAChR subunit stoichiometry also can be changed by altering the relative abundance of α and β subunits. Thus, changing the subunit stoichiometry of receptors by selective up- or down-regulation of the expression level of specific subunits seems to be a more general mechanism to tune the properties of ligand-gated ion channels. The current observation that agonist and antagonist sensitivities depend on subunit stoichiometry provides a rational basis for the existence of heteromeric neuronal nAChRs.
Acknowledgments
We thank Dr. Jim Patrick (Baylor College of Medicine, Houston, TX) for donating the cDNA clones of nAChR subunits, Kees Koster (Hubrecht Laboratory, Utrecht, The Netherlands) for supplyingX. laevis oocytes, John Rowaan for taking care of the frogs in our laboratory, and Ing. Aart de Groot for excellent technical assistance.
Footnotes
- Received May 18, 1998.
- Accepted September 14, 1998.
-
Send reprint requests to: Dr. R. Zwart, Research Institute of Toxicology, Utrecht University, P.O. Box 80.176, NL-3508 TD Utrecht, The Netherlands. E-mail: r.zwart{at}ritox.vet.uu.nl
-
This work was financially supported by Netherlands Organization for Scientific Research (NWO) Grant 903–42-011.
Abbreviations
- nAChR
- nicotinic acetylcholine receptor
- ACh
- acetylcholine
- ANOVA
- analysis of variance
- d-TC
- d-tubocurarine
- HEPES
- 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
- The American Society for Pharmacology and Experimental Therapeutics